| 7 | Role of imaging biomarkers in mutation-driven non-small cell lung cancer显示文摘Lung cancer remains the leading cause of cancer-related deaths worldwide.The treatment of non-small cell lung cancer(NSCLC),which accounts for a vast majority of lung cancers,has shifted to personalized,targeted therapy following discoveries of several targetable oncogenic mutations.Targeting of specific mutations has improved outcomes in many patients.This success has led to several target-specific agents replacing chemotherapy as first-line treatment in certain mutated NSCLC.Several researchers have reported that there may be imaging biomarkers that may be predictive of the presence of these mutations.These features,when present,have the potential in triaging patients into the most appropriate diagnostic and treatment algorithms.Distinct imaging features and patterns of metastases that have been associated with NSCLC with various targetable oncogenic mutations are presented in this review. | Dexter P Mendoza Zofia Piotrowska Jochen K Lennerz Subba R Digumarthy | 2020 | World Journal of Clinical Oncology2020，11，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员